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Key Points
• Bortezomib consolidation
after ASCT improves PFS in
myeloma.
• Improvement of response
is seen with bortezomib
consolidation after ASCT in
myeloma.
The Nordic Myeloma Study Group conducted an open randomized trial to compare
bortezomib as consolidation therapy given after high-dose therapy and autologous
stem cell transplantation (ASCT) with no consolidation in bortezomib-naive patients
with newly diagnosed multiple myeloma. Overall, 370 patients were centrally randomly
assigned 3 months after ASCT to receive 20 doses of bortezomib given during 21 weeks
or no consolidation. The hypothesis was that consolidation therapy would prolong
progression-free survival (PFS). The PFS after randomization was 27 months for the
bortezomib group compared with 20 months for the control group (P 5 .05). Fifty-one
of 90 patients in the treatment group compared with 32 of 90 controls improved their
response after randomization (P 5 .007). No difference in overall survival was seen.
Fatigue was reported more commonly by the bortezomib-treated patients in self-reported quality-of-life (QOL) questionnaires,
whereas no other major differences in QOL were recorded between the groups. Consolidation therapy seemed to be beneficial for
patients not achieving at least a very good partial response (VGPR) but not for patients in the ‡ VGPR category at randomization.
Consolidation with bortezomib after ASCT in bortezomib-naive patients improves PFS without interfering with QOL. This trial was
registered at www.clinicaltrials.gov as #NCT00417911. (Blood. 2013;121(23):4647-4654)
Introduction
Treatment with high-dose melphalan followed by autologous stem
cell transplantation (ASCT) has improved survival in patients with
multiple myeloma1-4 and remains the gold standard for younger
patients even in the era of new drugs.4 In a previous study, we
showed that a reduced initial therapy induced less toxicity but with
no reduction in treatment efﬁcacy.5 Building on these results, we now
aim to explore if consolidation therapy after ASCT could improve
treatment results. The proteasome inhibitor bortezomib has also
proved to be very efﬁcient as a relapse treatment for patients who
have previously undergone ASCT.6 In this open, multicenter
phase 3 randomized trial, we compared the effect of bortezomib
consolidation initiated 3 months after ASCT with no consolida-
tion, which was standard procedure within the Nordic countries
at the time the study began. Importantly, patients included in this
trial did not receive bortezomib as part of induction therapy. The
primary objective of the study was to determine whether the addition
of bortezomib consolidation would improve progression-free survival
(PFS).
Knowing that many patients have a high quality of life (QOL)
during the ﬁrst period of disease control7 and that consolidation
might interfere with this, we also focused on toxicity and QOL during
the study period.
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Methods
Study design and patients
The study was undertaken at 23 centers in Denmark, Estonia, Finland, Iceland,
Norway, and Sweden. Patients were enrolled between October 2005 and April
2009. The clinical data cutoff was April 2010 when the last randomized patient
had been followed for 12 months. An extra update for overall survival (OS)
was performed in April 2011. The primary end point was PFS, and secondary
end points were response rate, OS, QOL, and tolerability.
Myeloma patients with newly diagnosed symptomatic and measurable
disease were eligible for inclusion in this trial. All patients had received initial
therapy followed by stem cell collection andASCT.The regimen used for initial
therapy was not mandated. However, the patients had to be bortezomib naive at
the time of inclusion. The most common initial treatment was Cy-Dex
(cyclophosphamide andhigh-dose steroids), used for 169out of 183 in the control
group and161 out of 187 in the consolidation group. Eight patients in both groups
received a combination of thalidomide and steroids, and the remaining patients
received vincristine, adriamycin and dexamethasone or similar combinations.
Patients were included at the time of ASCT but randomized 3 months later.
Exclusion criteria were neuropathy . grade 2 according to National
Cancer Institute Common Toxicity Criteria, severe heart disease including
myocardial infarction within 6 months before enrollment, heart failure, New
York Heart Association > Class III or cardiac amyloidosis, history of
hypotension, or previous exposure to bortezomib.
All patients signed a written informed consent before inclusion. The
study was approved by the ethical committees and health authorities in
all participating countries and conducted in accordance with the 1975
Declaration of Helsinki and the Guidelines for Good Clinical Practice.
Randomization
Patients were randomly assigned in a 1:1 ratio 3 months after ASCT to receive
20 doses of bortezomib during 21 weeks starting no later than within 2
weeks after randomization or to no further treatment. Stratiﬁcation factors
were age (,60 years vs>60 years) and single vs double ASCT. The clinical
investigators at each site called the research unit at Lunds University Hospital
where randomization was performed using a computerized system.
Consolidation therapy
Bortezomib was given as a single drug intravenously in 6 cycles. In the ﬁrst
2 cycles, bortezomib was given twice weekly on days 1, 4, 8, and 11 in a
3-week schedule, followed by 4 cycles in which bortezomib was given once
weekly on days 1, 8, and 15 in a 4-week schedule. The starting dose was
1.3 mg/m2, but subsequent doses could be reduced due to neuropathy and/
or hematologic toxicity according to the standard prespeciﬁed dose-modiﬁcation
algorithm. No doses were postponed. If, for any reason, a dose could not be
administered, it was reported as reduced to 0. In total, a maximum of 20 doses
were given during 21 weeks. No corticosteroids, apart from a dose equivalent
to ,50 mg prednisone daily for no more than 1 week due to other medical
conditions, or any other antineoplastic drugs were allowed. A total of 6 patients,
1 control and 5 bortezomib-treated patients, did receive steroids: 3 due
to chronic obstructive lung disease and 1 each for vasculitis, hemolytic anemia,
and high fever. In 1 case, the dose was higher than permitted, and that
patient was censored at the time steroid treatment was started. Bisphospho-
nates were administered according to national guidelines.
Diagnostic, response, and relapse criteria
Symptomatic myeloma was deﬁned using the criteria of the International
Myeloma Working Group.8 Disease response and relapse were deﬁned
according to the European Group for Blood and Marrow Transplantation9
incorporating near complete response (nCR)10 and very good partial
response (VGPR).11 Because immunoﬁxation data were lacking in
a proportion of patients, nCR and CR are reported together. Patients with
no measurable M protein but for whom no bone marrow examination
conﬁrming CR was performed were included in the VGPR group.
Follow-up evaluation
All patients were evaluated with serum and urine electrophoresis monthly
for the ﬁrst year and then every second month until disease progression.
A bone marrow examination needed to be done to conﬁrm CR. All data were
reviewed according to Good Clinical Practice criteria by an independent
academic contract research organization. After disease progression, patients
were followed for survival. Survival time was measured from random-
ization, that is, 3 months after ASCT until disease progression or death from
any cause (PFS) or death from any cause (OS).
Health-related quality of life
Health-related quality of life (HRQOL) was assessed prospectively by use
of the European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30, version 3.0).12
Scoring of the EORTC QLQ-C30 was performed according to published
methods.13 The questionnaire has previously been shown to be reliable and
valid for myeloma patients.14
The questionnaires were ﬁlled in at baseline (time of randomization), at
8 weeks after randomization, and then every 3 months until 2 years and every
6 months until 3.5 years. The baseline questionnaires were administered by
a physician or nurse and were ﬁlled in by the patients before randomization.
The subsequent sets of questionnaires were mailed to the patients’ homes
with a stamped return envelope.
Statistical analysis
The hypothesis of this study was that consolidation treatment with bortezomib
would prolong median PFS by 12 months. To demonstrate this with a
power of 80% and a signiﬁcance level of 5% (2-sided test), 396 patients
needed to be included, of whom at least 80% would be randomized (ie, at
least 159 patients per arm).
The proportions of patients with a given characteristic were compared
using Fisher’s exact test for variables with frequency scale and Mann-Whitney
U test for the remaining variables. A Mann-Whitney U test was also used
to calculate the signiﬁcance of differences in the EORTC QLQ-C30 score
between the control group and bortezomib group. Based on previous work
with myeloma patients, the minimal important difference in an HRQOL
scale score was classiﬁed as a difference of at least 6 points (0-100 scale).15
PFS and OS rates were calculated according to the Kaplan-Meier method,
and survival comparisons between groups were made by the log-rank test.
PFS and survival were calculated from randomization (ie, 3 months after
high-dose therapy and ;6 months after start of induction therapy). The
statistical analyses were performed in SPSS Statistics 18 for Windows
(IBM Corporation, Somers, NY).
Results
Patients and baseline characteristics
Figure 1 shows the study proﬁle. Four hundred and three patients were
included at the time of ASCT. A total of 4 patients were excluded due
to nonsecreting disease (2) or not fulﬁlling diagnostic criteria (2). Of
the remaining 399 patients, 29 were not randomized due to withdrawn
consent (17), neuropathy (4), progressive disease before randomiza-
tion (4), logistic reasons (2), early death (1), or severe infection (1).
Of the remaining 370 patients, 187 were randomized to bortezomib
consolidation therapy and 183 to the control group.
Baseline characteristics are shown in Table 1. All variables
were equally distributed between the 2 groups.
Completion of consolidation treatment
The median number of bortezomib injections received was 19, and
the median given dose was 90% (calculated as the total given dose
divided by total planned dose for each patient).
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Survival
The overall median follow-up time was 38 months. The median PFS
was prolonged for patients randomized to bortezomib consolida-
tion (27 months vs 20 months, P 5 .05) (Figure 2A).
Patients achieving at least VGPR at any time experienced a
signiﬁcantly longer PFS compared with those who did not
(28 months vs 16 months, P , .001) irrespective of whether the
patient was randomized to bortezomib treatment or not (Figure 2B).
The beneﬁcial effect of bortezomib consolidation was only seen
in patients not achieving at least VGPR after ASCT (Figure 2C-D).
Further, no difference in PFS was seen in patients in the >VGPR
category at randomization compared with those improving their
response to >VGPR during the study (data not shown).
Because only 15 patients underwent a double ASCT, no
meaningful statistics could be calculated comparing single and
double ASCT. No difference in PFS was seen for patients under
the age of 60 years compared with those aged 60 or over (data not
shown). After 3 years of follow-up, the OS was similar in both
treatment groups, ;80% (Figure 2E).
Response rate
The response rates at randomization 3 months after ASCT and best
response during the study, calculated on an intention-to-treat basis,
are presented in Table 2. At randomization there was no difference
in response rate between the groups;;20% of all randomized patients
had achieved CR/nCR, and ;40% had achieved at least VGPR.
Measured as best response achieved during the study, there was a
difference with more bortezomib-treated patients achieving at least
VGPR (71% vs 57%, P , .01) and a trend toward more patients
achieving CR/nCR (45% vs 35%, P 5 .055). Improvement of
response from partial response (PR) to at least VGPR was also
more common in patients receiving bortezomib consolidation (51
of 90 patients [57%] vs 32 of 90 [36%], P 5 .007).
Toxicity
Sensory peripheral neuropathy was reported by 57% of patients in
the treatment group vs 24% in the control group. Neuropathic pain
was reported by 34% and 12%, respectively. Sensory neuropathy .
grade 2 on the Common Toxicity Criteria scale was experienced by
5% of bortezomib-treated patients vs 1% for controls (P , .04),
whereas neuropathic pain . grade 2 was experienced by 6% vs 1%
(P , .006) (Figure 3).
Figure 1. Flow diagram of 403 patients included in the Nordic Myeloma Study Group bortezomib consolidation study.
Table 1. Baseline characteristics
Variable
Bortezomib
(n 5 187)
Control
(n 5 183)
Age, years* 59.1 (9.90) 58.7 (8.80)
Male† 59 (111) 60 (109)
Double ASCT† 5 (9) 3 (6)
Myeloma subtype† n 5 187 n 5 183
IgG 55 (103) 63 (116)
IgA 26 (50) 21 (39)
Light chain 18 (33) 14 (25)
Other 1 (1) 2 (3)
ISS disease stage† n 5 125 n 5 141
I 38 (48) 41 (58)
II 38 (48) 31 (44)
III 23 (29) 28 (39)
b2-microglubilin (mg/L)‡ 3.0/4.9 3.4/5.1
Albumin (g/L)‡ 36.8/35.8 37.0/36.2
Creatinine (mmol/L)‡ 82.0/118.1 83.0/123.1
Hemoglobin (g/L)‡ 112.0/114.1 110.0/111.7
Platelets (3109/L)‡ 249.0/252.9 243.0/253.9
Fluorescence in situ hybridization
analysis for cytogenetic abnormalities†
n 5 73 n 5 66
Absence of del(13q), t(4;14), or del(17p) 75.3 (55) 63.7 (42)
Presence of del(13q)§ 21.9 (16) 16.7 (11)
Presence of t(4;14) and/or del(17p) 19.2 (14) 19.7 (13)
ISS, International Staging System.
*Median (interquartile range).
†% (n).
‡Median/mean.
§Regardless of absence or presence of t(4;14) and/or del(17p).
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Hematologic toxicity was mild and manageable. It seemed as if
the reduction of neutrophil and platelet counts was less pronounced
during the last 4 treatment cycles when bortezomib was given once
weekly (Figure 4).
Two cases of secondary primary malignancy were re-
ported. One of the bortezomib-treated patients developed breast
cancer, and 1 patient in the control group developed rectal
cancer.
Figure 2. Analysis of outcome from start of consolidation therapy. Kaplan-Meier estimates of PFS for bortezomib-treated patients vs controls (A), PFS for patients
achieving $VGPR vs patients achieving ,VGPR (B), PFS for patients in the ,VGPR category at randomization (C), PFS for patients in the $VGPR category at
randomization (D), and OS for bortezomib-treated patients vs controls (E).
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HRQOL
Baseline questionnaires were available for 311 patients (84%).
There were no signiﬁcant differences in HRQOL score between the
bortezomib group and the control group at baseline.
After 8 weeks, there was a statistically signiﬁcant increase in
fatigue and nausea/vomiting in the bortezomib group (P , .01).
However, only the fatigue scale reached what we previously had
set as a cutoff for clinically relevant changes (6 points on a 0-100
scale) (Figure 5). There were no signiﬁcant differences in HRQOL
scores between the bortezomib group and the control group during
the rest of the study period.
Discussion
This randomized, multicenter phase 3 trial in newly diagnosed
myeloma patients showed that consolidation with bortezomib after
ASCT did improve response and resulted in a statistically signiﬁcant
7-month prolongation of PFS in bortezomib-naive patients. However,
the study hypothesis of a 12-month prolongation of PFS was not
conﬁrmed. Our data indicate that the prolongation of PFS was
mediated by an increased proportion of patients achieving an
improvement in the quality of the response after bortezomib con-
solidation. Supporting this theory are the ﬁndings that the proportion
of patients improving their grade of response was signiﬁcantly
higher for the treatment group and that the beneﬁcial effect of
bortezomib consolidation on PFS only was seen in patients not
achieving at least VGPR after ASCT. Finally, there was no difference
in PFS for patients in the >VGPR category after ASCT compared
with those who achieved it later during the study.
No difference in OS was seen, and this could be due to the fact
that treatment at progression today is very effective and there are
many treatment options. More patients in the control group did receive
bortezomib-containing combinations after ﬁrst relapse, 48 vs 19.
Apart from this, there were small differences in second-line therapy;
a second ASCT was given to 17 controls and 18 patients receiving
bortezomib consolidation; thalidomide, 25 vs 27; lenalidomide, 2
vs 9; chemotherapy combinations, 10 vs 13; and radiation alone,
10 vs 4. A landmark analysis starting at the time of relapse did not
show any difference in estimated OS (4.0 years for controls vs 3.9
years for patients randomized to consolidation).
The role of consolidation and maintenance therapy is still unclear
in myeloma therapy. The earliest experiences with chemotherapy
were disappointing,16,17 and the beneﬁcial effect of corticosteroids
as single-drug maintenance18 has been questioned.19 Meta-analyses
of interferon a have shown a positive effect but at the cost of sub-
stantial tolerability problems.20 Several studies have shown pro-
longed PFS, and some even prolonged OS when thalidomide has
been given as consolidation or maintenance after ASCT but with
substantial toxicity, mainly neurologic.21 An interesting ﬁnding in
the French study, Intergroup Francophone du Mye´lome (IFM)
99-02, is that the beneﬁcial effect of thalidomide was only seen
in patients achieving less than VGPR after ASCT.22 Hence, the
effect of thalidomide in the IFM study and of bortezomib in our
study both seem to have been mediated by improving the degree
of treatment response. In contrast, data from the British study,
Medical Research Council IX, indicate that the effect of thalidomide
given after ASCT has an effect of maintenance more than consoli-
dation because the beneﬁcial effect of thalidomide treatment did not
differ due to response after ASCT.23 Similar results were seen in
2 studies using lenalidomide as maintenance therapy after ASCT.24,25
Regardless of response after ASCT, this treatment approach seemed
to be beneﬁcial.
Table 2. Response rates
Variables
Bortezomib Control Test*
n % (n) n % (n) P value
At randomization 179† 180†
$nCR 20.1 (36) 20.6 (37)
VGPR 19.6 (35) 18.3 (33)
PR 51.4 (92) 50.0 (90)
MR 7.3 (13) 8.9 (16)
SD 1.7 (3) 2.2 (4)
Best response 182‡ 183
$nCR 45.1 (82) 35.0 (64)
VGPR 25.8 (47) 22.4 (41)
PR 25.3 (46) 38.3 (70)
MR 2.7 (5) 3.3 (6)
SD 0.5 (1) 0.5 (1)
PD 0.5 (1) 0.5 (1)
$nCR 45.1 (82) 35.0 (64) .055
$VGPR 70.9 (129) 57.4 (105) .0088
MR, minor response; SD, stabile disease; PD, progressive disease.
*Fisher’s exact test, exact significance (2-sided).
†Eleven patients had unconfirmed responses at the time of randomization.
‡Five patients had incomplete follow-up.
Figure 3. Neurologic toxicity. Number of patients experiencing neuropathic pain
(A) and peripheral sensory neuropathy (B) by treatment arm.
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In recent years, several studies and meta-analyses indicate that
achievement of complete response or at least VGPR after ASCT
is associated with a better outcome.26,27 These data support the
consolidation concept (ie, to apply a short course of treatment in
order to reduce the number of residual tumor cells), which is shown
by improved response status in patients with insufﬁcient response
after ASCT.
Consolidation with bortezomib after ASCT in combination with
other drugs has been reported. In a recently published update, it
was shown that the combination of bortezomib, thalidomide,
and dexamethasone is superior to thalidomide and dexamethasone
alone, given as consolidation therapy after double ASCT. In this
study, the same combinations are also used as initial therapy before
ASCT. Using a landmark analysis, Cavo et al28 showed that the
superior results of the triplet combination over the double are
further improved by consolidation therapy and the beneﬁcial effect
is most evident in patients not achieving at least nCR after ASCT.
Even if it is dubious to compare results between studies, PFS in the
Italian study is clearly longer than in our study, indicating that using
different drugs in combination can be very effective as consoli-
dation therapy. When our study was planned, there were already
data suggesting that corticosteroids did improve the effect of
bortezomib in the relapse setting.10,29 However, because studies
have implied that steroids do have an effect of their own given
as consolidation therapy, we chose to give bortezomib as a single
drug, avoiding confusion about the results.
A weakness in the present study is that a repeat bone marrow
examination was not always performed in order to conﬁrm or reject
CR. Patients with no measurable M protein but for whom no bone
marrow examination conﬁrming CR was performed were down-
graded to VGPR. This means that patients in the VGPR response
category are a heterogeneous group containing both patients in true
CR as well as patients with only a 90% reduction of the original M
protein. Unfortunately, cytogenetics was not available for more than
a proportion of the patients. The reason for this was that ﬂuorescence
in situ hybridization analysis was not standard at the time of the
study in the Scandinavian countries, and in addition, the study was
performed at smaller local hospitals with limited access to cytogenetic
techniques.
An interesting and important ﬁnding that limits the difference
between the 2 patient groups in this study is that ;17% of the
controls also improved their response. However, in the clinic, it
is not a rare ﬁnding that patients do improve their response up to
1 year after ASCT.
Some of the strengths of the study are that bortezomib was given
as a single drug, meaning that observed effects can only be attributed
to this substance. Further, the QOL data show that the additional
therapy did not interfere with QOL, which is very important when
focusing on PFS. The risk of neurotoxicity might be reduced with a
more restrictive dose-modiﬁcation algorithm, and our study showed
that the hematologic toxicity was more pronounced when bortezomib
was given twice weekly compared with once weekly. The only
signiﬁcant differences in QOL, fatigue and nausea/vomiting after
7 weeks, also disappeared when the less frequent dose schedule
was used. For elderly patients, it has already been suggested that
administration of bortezomib once weekly makes the treatment
more tolerable.30 Also, modiﬁcation of administration might be
beneﬁcial because now there are data showing that by administering
bortezomib subcutaneously instead of intravenously the incidence
and severity of neuropathy can be signiﬁcantly reduced.31
In conclusion, our study shows that consolidation with bortezo-
mib after ASCT improves PFS and indicates that this is due to im-
provement of response. The treatment was well tolerated as indicated
by no important interference with QOL, low frequency of severe
toxicity, and that most patients received their treatment without
any dose reduction. The relatively short treatment period might
have been a reason for the good tolerability. Results from other
studies imply that efﬁcacy might be enhanced if bortezomib is
given in combination with other agents and that tolerability could
be even further improved enhancing the possibility of long-term
treatment.
Figure 4. Hematologic toxicity. Mean neutrophil (A) and platelet (B) count for
patients randomized to bortezomib during the consolidation period. ANC, absolute
neutrophil count.
Figure 5. Quality of life. Score for fatigue by treatment arm.
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